Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

@article{Ratner2004AmylinRW,
  title={Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.},
  author={Robert E. Ratner and Robert P. Dickey and Mark S Fineman and David Maggs and Larry Z. Shen and Susan A Strobel and Christian Weyer and Orville G. Kolterman},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={2004},
  volume={21 11},
  pages={1204-12}
}
AIMS The autoimmune-mediated destruction of pancreatic beta-cells in Type 1 diabetes mellitus renders patients deficient in two glucoregulatory peptide hormones, insulin and amylin. With insulin replacement alone, most patients do not achieve glycaemic goals. We aimed to determine the long-term efficacy and safety of adjunctive therapy with pramlintide, a synthetic human amylin analogue, in patients with Type 1 diabetes. METHODS In a double-blind, placebo-controlled, parallel-group… CONTINUE READING